Jacob Borodovsky, PhD
Senior Research Scientist, Center for Technology and Behavioral Health and the Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth
Jacob Borodovsky is a Senior Research Scientist and Epidemiologist at CTBH and the Department of Biomedical Data Science in the Dartmouth Geisel School of Medicine. He received his PhD from the Dartmouth Institute for Health Policy and Clinical Practice under the mentorship of Drs. Lisa Marsch, Alan Budney, and Emily Scherer. He completed his postdoctoral training at the Washington University School of Medicine in St. Louis under the mentorship of Drs. Richard Gruzca and Laura Bierut and was awarded an NRSA F32 fellowship by the National Institute on Alcohol Abuse and Alcoholism during this time. Broadly speaking, Jake’s research interests lie at the intersection of addiction, epidemiology, statistical methods, and policy. He enjoys thinking about and trying to answer questions such as, “Why do humans use drugs?” “What is the best way to measure drug use?” and “What happens to drug use behaviors when we try to modify them with population-level regulations and individual-level interventions?” To answer these kinds of questions, Jake utilizes a range of traditional and non-traditional data collection and analysis methods and studies topics such as (1) cannabis legalization and novel methods of cannabis administration, (2) medication and technology-based treatments for opioid use disorder, (3) national patterns of co-use of alcohol and prescription central nervous system depressant medications (e.g., prescription benzodiazepines), (4) and risk behavior propensity among adolescents.
Jake enjoys good food, reading, hiking, and any documentary film done by Ken Burns. Pre-Covid, he was really into Brazilian Jiujitsu and hopes to get back to that training soon.
Selected Publications
- Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014 Sep;47(3):202-12. doi: 10.1016/j.jsat.2014.04.006. PMID: 24953168; PMCID: PMC4180514.
- Schuman-Olivier Z, Connery H, Griffin ML, Wyatt SA, Wartenberg AA, Borodovsky J, Renner JA Jr, Weiss RD. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013 Nov-Dec;22(6):574-80. doi: 10.1111/j.1521-0391.2013.12024.x. PMID: 24131165; PMCID: PMC3801272.
- Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ. Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. doi: 10.1016/j.drugalcdep.2013.04.006. PMID: 23688843; PMCID: PMC3916951.